Castle Biosciences Inc(CSTL) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 11 at 4:27 PM ET (Korea 9/12 05:27)
Full metrics table
| Index | RUT | P/E | - | EPS (ttm) | -0.65 | Insider Own | 2.13% | Shs Outstand | 30.5M | Perf Week | -0.98% |
| Market Cap | 0.99B | Forward P/E | - | EPS next Y | 22.27% | Insider Trans | -37.52% | Shs Float | 29.9M | Perf Month | 2.86% |
| Enterprise Value | 0.76B | PEG | - | EPS next Q | -0.36 | Inst Own | 90.33% | Short Float | 6.61% | Perf Quarter | 53.88% |
| Income | -0.02B | P/S | 2.76 | EPS this Y | -53.28% | Inst Trans | -0.93% | Short Ratio | 5.03 | Perf Half Y | 27.69% |
| Sales | 0.36B | P/B | 2.1 | EPS next 5Y | 24.16% | ROA | -3.51% | Short Interest | 1.98M | Perf YTD | -16.89% |
| Book/sh | 15.41 | P/C | 3.7 | EPS past 3/5Y | 31.36% -8.93% | ROE | -4.2% | 52W High | -26.99% ($44.28) | Perf Year | 42.11% |
| Cash/sh | 8.73 | P/FCF | - | Sales past 3/5Y | 35.94% 40.6% | ROIC | -3.86% | 52W Low | 82.43% ($17.72) | Perf 3Y | 72.33% |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -100.37% | Gross Margin | 74.13% | Volatility(W/M) | 4.02% 5.13% | Perf 5Y | -56.59% |
| Dividend TTM | - | EV/Sales | 2.12 | Sales Y/Y TTM | 3.18% | Oper. Margin | -8.99% | ATR (14) | 1.51 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 5.85 | EPS Q/Q | -144.28% | Profit Margin | -5.43% | RSI (14) | 54.58 | Recom | 1.11 |
| Dividend Gr. 3/5Y | - | Current Ratio | 6.04 | Sales Q/Q | 20.14% | SMA20 | -1.06% ($32.68) | Beta | 0.96 | Target Price | $44 |
| Payout | - | Debt/Eq | 0.08 | Earnings | 2026/7/30 | SMA50 | 11.63% ($28.96) | Rel Volume | 0.51 | Prev Close | $32.32 |
| Employees | 883 | LT Debt/Eq | 0.07 | EPS/Sales Surpr. | 82.8% 20.07% | SMA200 | 10.12% ($29.36) | Avg Volume(3M) | 0.39M | Price | $32.33 |
| IPO | 2019/7/25 | Option/Short | Yes/Yes | Trades | 5588 | Volume | 201,925 | Change | 0.03% |
Company
CSTL is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
🧬 Castle Biosciences is a US-based molecular diagnostics company specializing in oncology. It offers proprietary gene expression test panels for diseases where clinical decision-making is particularly challenging, including skin cancers and other cutaneous tumors, uveal melanoma, and Barrett's esophagus. The core value proposition is helping physicians more accurately predict treatment direction and recurrence risk based on test results.
Over the past 1 year, roughly in the middle
27% below its 1-year high.
CSTL has weak earning power
Losses or thin margins. Early-stage growth or weakening competitiveness
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -53.3% this year.
Tap to view numbers
The stock looks undervalued
Trading at - times earnings.
Tap to view numbers
Results came in about as expected
Slight tendency to beat estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Strong Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by +72.3% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 90.3%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
XHS 0.01%
HAPS 0.00%
SVAL 0.00%
DWAS 0.00%
FYC 0.00%It ranks #4 in the industry
Based on market cap of $988M.
CSTL $988M PER -
TMO $225B PER 32.8
DHR $141B PER 35.5
NTRA $47B PER -
FAQ
What kind of company is CSTL?
CSTL belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of CSTL?
The market cap of CSTL is approximately $988M, ranking 2,657 within its sector.
What is the 52-week high and low for CSTL?
CSTL has recorded a 52-week high of $44.28 and a low of $17.72.
